House Lawmakers Say FDA Generic Backlog Impedes Market Competition

February 4, 2016 at 3:11 PM
Amidst the drama surrounding former Turing Pharmaceuticals CEO Martin Shkreli’s refusal to answer congressional inquiries on drug pricing, FDA also caught fire at a House oversight committee hearing Thursday (Feb. 4) where Chairman Jason Chaffetz (R-UT) said the agency has failed its statutory responsibilities to eliminate the generic drug backlog and ensure competition for companies that hike the price of prescription drugs. FDA's drug center chief responded that the agency is clearing out the backlog, but also pointed to deficient...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.